Efficacy of SGLT2 Inhibitors in Adults With Sepsis

Sponsor
Hospital Authority, Hong Kong
Study ID
NCT06473844
Status
Recruiting
Apply to this trial

Conditions

  • Critically Ill
  • Inflammation
  • Organ Dysfunction Syndrome
  • SGLT2 Inhibitors
  • Sepsis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 10 MG — DRUG
    Empagliflozin 10mg once daily from recruitment to hospital discharge
  • Placebo — DRUG
    Placebo single tablet once daily from recruitment to hospital discharge

Study Details

Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows: (i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis. (ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.

Key Dates

Start date
Mar 5, 2025
Status verified
Oct 2024
Primary completion
Feb 28, 2027
Completion
Feb 28, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: SGLT2 inhibitor empagliflozin
    10mg daily from recruitment to hospital discharge
  • Placebo Comparator: Placebo
    1 tablet daily from recruitment to hospital discharge

Primary Outcome Measure

Mortality [ Time Frame: 28-day mortality ]

Central Contacts

Related Studies